Sleep Apnea Impairs Neurovascular Control in HF
To better understand the implications of this highly prevalent disorder, it is critical to understand its physiological sequelae. In a large, undifferentiated cohort of HF patients with systolic dysfuntion, we found that chemoreceptor stimulation led to significantly reduced muscle blood flow compared with age-matched healthy individuals. 17 More recently, we demonstrated that the reduced muscle blood flow was because of both endothelial dysfunction and exaggerated sympathetic nerve activity. 18 However, whether these physiological sequelae of chemoreceptor stimulation were present in the subpopulation with SDB was not determined but is critical because it is this subpopulation that experiences repetitive chemoreceptor activation during recurrent sleep apneic episodes. Intermittent hypoxic cycles (oxygen desaturation and reoxygenation) during the sleep apnea periods in non-HF populations lead to endothelial dysfunction [20] [21] [22] and increase in sympathetic nerve activity. [23] [24] [25] In addition, there is evidence that SDB increases MSNA in patients with HF. 26, 27 Unknown is whether SDB exacerbates the muscle vasoconstriction during peripheral and central chemoreceptors stimulation. It is highly likely that this association is also present in patients with HF. Increased vasoconstriction and sympathetic activation would be expected to worsen hemodynamics and increase arrhythmia risk in HF patients with systolic dysfunction.
In this study, we hypothesized that (1) the muscle vasoconstriction responses to hypoxia and hypercapnia would be more pronounced in HF patients with SDB than in HF patients without SDB (NoSDB) and (2) this alteration in vascular responses would be associated with endothelial dysfunction and exaggerated MSNA responses.
Methods

Subjects
Ninety patients with HF were screened for the study, and 41 patients with HF, aged 30 to 65 years old, LVEF ≤40%, functional class II-III, New York Heart Association, optimal medical therapy, and peak oxygen uptake (V ⋅ O 2 ) ≤20 mL kg −1 per min were enrolled. The exclusion criteria were myocardial infarction within 3 months, unstable angina, acute HF, pacemaker, pulmonary disease, chronic renal disease, peripheral neuropathy, history of stroke, untreated hypo/hyperthyroidism, or body mass index >30 kg/m 2 . The study was approved by Human Subject Protection Committee of the Heart Institute (InCor; SDC-3656/11/074) and Clinical Hospital, School of Medicine, University of São Paulo (CAPPesq; 0672/11). All subjects gave written informed consent to participate in the study.
Measures and Procedures
Sleep Study
All patients underwent full polysomnography (Embla N7000; Medcare Flaga, Reykjavik, Iceland) in a 1-night study performed at the sleep laboratory. Sleep stages, apneas, hypopneas, and arousals were defined and scored as previously described. 28 In brief, apnea was defined as complete cessation of airflow for at least 10 s. Hypopnea was defined as a reduction in respiratory signal ≥30% from baseline for at least 10 s associated with oxygen desaturation ≥3% or arousal. The apnea-hypopnea index (AHI) was calculated by the total number of respiratory events (apneas and hypopneas) per hour of sleep. Patients with AHI ≥15 events per hour during sleep were defined as having SDB.
Cardiopulmonary Exercise Test
Maximal exercise capacity was determined during a maximal incremental exercise test on cycle ergometer (Via Sprint 150P; Ergoline, Bitz, Germany), using a ramp protocol with work rate increments of 5 to 15 W every minute until exhaustion. V ⋅ O 2 and carbon dioxide production were determined by means of gas exchange on a breathby-breath basis in a computerized system (Vmax Encore 29 System; VIASYS Healthcare Inc, Yorba Linda, CA). Peak V ⋅ O 2 was defined as the maximum attained V ⋅ O 2 at the end of the exercise period in which the subject could no longer maintain the cycle ergometer velocity at 60 rpm. 29 Peak V ⋅ O 2 was an inclusion criterion (peak V ⋅ O 2 ≤20 mL kg −1 per min). 30 In addition, this parameter confirmed the similarity in functional capacity between groups.
Cardiac Function
LVEF was determined from the 2-dimensional echocardiography by Simpson method (Vivid E9; GE Healthcare, Wauwatosa, WI). 31
Muscle Sympathetic Nerve Activity
MSNA was directly measured from the peroneal nerve using the technique of microneurography, as previously described. 32 In brief, signals were amplified by a factor of 50 000 to 100 000 and bandpassed filtered (700-2000 Hz). For recordings and analysis, nerve activity was rectified and integrated (time constant: 0.1 s) to obtain a mean voltage display (662C-4 Nerve Traffic Analysis System; The University of Iowa, Iowa City, IA). Muscle sympathetic bursts were identified by visual inspection by one of the investigators (C.E.N.) blinded to the study protocol. MSNA was expressed as burst frequency (bursts per minute).
Blood Flow
Forearm blood flow (FBF) and calf blood flow (CBF) were measured simultaneously by venous occlusion plethysmography. 33 The resting nondominant arm and leg were elevated above heart level to ensure adequate venous drainage. A mercury-filled silastic tube attached to a lowpressure transducer was placed around the forearm, 5 cm distant from the humeroradial joint, and around the largest calf circumference and connected to a plethysmography (AI6; D. E. Hokanson Inc, Bellevue, WA). Sphygmomanometer cuffs were placed around the wrist and upper arm and around the thigh and ankle. At 15-s intervals, the upper arm and thigh cuffs were inflated above venous pressure for 7 to 8 s. The increase in the tension in the silastic tube reflects the increase in the forearm and calf volume and, consequently, the vasodilation. FBF and CBF were analyzed by one of the investigators (C.E.N.) blinded to the study protocol. Forearm vascular conductance (FVC) and calf vascular conductance (CVC) were calculated by dividing mean blood pressure by FBF and CBF, respectively, and expressed in units.
Blood Pressure and Heart Rate
Blood pressure was noninvasively evaluated on beat-to-beat basis by means of a finger photoplethysmography (Finometer Pro; Finapres Medical Systems, Amsterdam, The Netherlands). 34 Heart rate was also recorded by Finometer Pro.
Peripheral and Central Chemoreflex Control
Peripheral chemoreflex control was evaluated through the inhaling of a hypoxic gas mixture (10% O 2 and 90% N 2 ), for a 3-minute period. 17 During stimulation of peripheral chemoreceptors by hypoxia, the influence of central chemoreceptors was minimized by the maintenance of isocapnia, with titrated carbon dioxide. Central chemoreflex control was evaluated through the inhaling of a hypercapnic gas mixture (7% CO 2 and 93% O 2 ) for a 3-minute period. 17 During stimulation of the central chemoreceptors by hypercapnia, the influence of peripheral chemoreceptors was minimized by hyperoxia. The sequence of interventions to evaluate peripheral and central chemoreceptors was randomized. Oxygen saturation (O 2 saturation) was monitored through a pulse oximeter (DX 2405 Oxypleth; Dixtal Biomedica, Manaus, Brazil), and endtidal carbon dioxide (P ET CO 2 ) was monitored with a capnograph (DX 1265 ETCO 2 Capnogard; Dixtal Biomedica). 35 Pulmonary ventilation (V ⋅ E ) was monitored by a pneumotachograph (3830 Series, Heated Linear Pneumotachometer; Hans Rudolph Inc, Kansas City, MO) and a differential pressure transducer (MP45; Validyne Engineering, Northridge, CA) coupled to a signal integrator (Gould Integrator Plug In Module 13-4615-70 Model A; Gould Instrument System. Inc, Valley View, OH). 35 The data analysis is described in details in the Data Supplement. Sleep Apnea Impairs Neurovascular Control in HF
Experimental Protocol
Protocol 1: Peripheral Chemoreceptor Stimulation. The purpose of this protocol was to study the impact of the peripheral chemoreceptor stimulation on FBF, CBF, and MSNA. After at least 2 hours of a light meal without caffeine, the participant's leg was positioned for microneurography, and a microelectrode was placed in the peroneal nerve. Then, electrodes were placed to monitor ECG; cuffs were placed to evaluate FBF and CBF and blood pressure; and mouthpiece and nasal clip were placed to allow gases inhalation. FBF, CBF, MSNA, heart rate, blood pressure, and V ⋅ E were recorded for 3 minutes, followed by 3 minutes of recording during inhalation of a hypoxic gas, with maintenance of isocapnia. Measurements were continuously conducted during the protocol. The medications were not held before the experiments.
Protocol 2: Central Chemoreceptor Stimulation. The purpose of this protocol was to study the impact of the central chemoreceptor stimulation on FBF, CBF, and MSNA. FBF, CBF, MSNA, heart rate, blood pressure, and V ⋅ E were recorded for 3 minutes, followed by 3 minutes during inhalation of a hypercapnic gas mixture. The physiological parameters were continuously monitored. Peripheral and central chemoreceptors stimulations were conducted in a randomized order. There was a 15-minute interval between the 2 experimental protocols to ensure that the variables returned to baseline.
Statistical Analysis
The data are presented as mean±SE of the mean or median (25th-75th percentiles). A χ 2 test was used to assess categorical data differences. The Kolmogorov-Smirnov and Levene tests were used to assess the normality of distribution and homogeneity for each variable. The baseline characteristics between groups were tested by unpaired Student t test. Non-normally distributed data were analyzed by Mann-Whitney U test. Linear mixed-effects models with 2 factors were used (patient as a random effect). It was supposed first-order autoregressive correlation matrix between time points. When significance was observed, post hoc comparisons were performed by Tukey-Kramer honest significant difference (HSD) test. We tested the null hypothesis (Ho) of identical response profiles for SDB and NoSDB groups. Further analysis excluding patients with diabetes mellitus and dyslipidemia was performed. In addition, the differences between patients with CSA and OSA were also tested. Spearman correlation was performed to analyze the relationships between the responses in hypoxia/hypercapnia and the presence of SDB. Probability values of P<0.05 were considered statistically significant. All statistical analyses were performed using STATISTICA 12 software (StatSoft Inc, Tulsa, OK) and SAS 8.0 software (SAS Institute Inc, Cary, NC).
Results
Baseline Measures
From a total of 90 patients with HF who were initially screened to the study, 49 patients were excluded: peak V ⋅ O 2 >20 mL kg −1 per min (23), LVEF >40% (8), body mass index >30 kg/ m 2 (4), atrial fibrillation (2), pulmonary disease (1), complex arrhythmia (1), under anxiolytic (1), technical problems during polysomnography study (1), refused to participate (1), and did not conclude all the evaluations (7) . Forty-one patients who fulfilled all the inclusion criteria were enrolled in the study: NoSDB (n=13, 46 [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] years) and SDB (n=28, 57 [54-61] years). In the SDB group, 6 patients had CSA, and 22 had OSA. All patients were clinically stable, and euvolemic, based on normal jugular venous pressure, and absence of orthopnea, body weight gain, pulmonary congestion, hepatomegaly, or lower limb edema. Baseline characteristics are shown in Table 1 . The percentage of women was greater in the NoSDB group compared with the SDB group. The SDB group was older than the NoSDB group. The functional class, HF cause, medications, peak V ⋅ O 2 , LVEF, and comorbidities (diabetes mellitus and hypertension) were not different between groups. There were more patients with dyslipidemia in the SDB group than the NoSDB group.
The polysomnographic characteristics are shown in Table 2 . As expected, the AHI was higher in the SDB group compared with the NoSDB group. The SDB group had higher percentage of light sleep (stages N1 and N2) and lower percentage of deep sleep (slow-wave sleep, N3) than the NoSBD group. Patients with SDB had lower total sleep time and sleep efficiency compared with the NoSDB group. SDB group had higher arousal index than the NoSDB group. About O 2 saturation, patients with SDB had lower minimum O 2 saturation than the NoSDB group.
Baseline heart rate, mean blood pressure, FBF, CBF, FVC, CVC, V ⋅ E , and P ET CO 2 were not significantly different between groups (Table 3 ). O 2 saturation was lower in the SDB group. Baseline MSNA was significantly higher in the SDB group (Table 3) . Hemodynamic and respiratory responses during hypoxia are displayed in Table 4 . Heart rate, mean blood pressure, V ⋅ E , and P ET CO 2 during hypoxia were similar between groups. During hypoxia, FBF and FVC responses were significantly lower in the SDB group versus the NoSDB group ( Figure 1A and 1B, respectively; Figure IA and IB in the Data Supplement). Similar results were found in CBF and CVC. The SDB group had lower CBF and CVC responses compared with the NoSDB group ( Figure 1C and 1D, respectively; Figure IC and ID in the Data Supplement). Further analysis showed that hypoxia tended to cause a more pronounced forearm vasoconstriction in patients with CSA than in patients with OSA (FBF: P=0.056; FVC: P=0.055; Figure IIA and IIB, respectively, in the Data Supplement). No differences in CBF and CVC were found ( Figure IIC and IID, respectively, in the Data Supplement). To rule out the possibility that potential comorbidities associated with endothelial dysfunction might mask our findings, an additional analysis was conducted excluding patients with diabetes mellitus and dyslipidemia. We found that FBF and FVC were significantly lower in the SDB group (n=10) compared with the NoSDB group (n=9; Figure IIIA and IIIB, respectively, in the Data Supplement). There were no differences in CBF and CVC responses between groups ( Figure IIIC and IIID, respectively, in the Data Supplement). During hypoxia, MSNA responses were significantly higher in the SDB group when compared with the NoSDB group ( Figure IVA in the Data Supplement) and tended to be higher (P=0.069) when analyzed by oxygen saturation levels (Figure 2A ). Further analysis showed no significant differences in MSNA responses between patients with CSA and OSA ( Figure VA in the Data Supplement). Finally, we found a significant correlation between the magnitude of change in MSNA, FBF, FVC, CBF, and CVC during hypoxia and the AHI ( Table I in 
Central Chemoreceptor Stimulation: Effects of Hypercapnia (Protocol 2)
Hemodynamic and respiratory responses during hypercapnia are displayed in Table 4 . Heart rate, mean blood pressure, and V ⋅ E responses to hypercapnia were not different between groups. During hypercapnia, FBF and FVC were significantly lower in the SDB group versus the NoSDB group ( Figure 3A and 3B, respectively; Figure VIA and VIB in the Data Supplement). In regard to calf vasoconstriction, hypercapnia caused greater CBF and CVC reduction in the SDB group compared with the NoSDB group ( Figure 3C 
Discussion
The main and new findings of this study are that (1) HF patients with SDB have more pronounced skeletal muscle Table 4 The physical characteristics and hemodynamic status show similarities between patients with SDB and patients without SDB. In contrast, the neurovascular control was different between these groups. Because recurrent intermittent hypoxia/hypercapnia episodes during sleeping increase sympathetic outflow, [23] [24] [25] it is not surprising that patients with SDB have increased MSNA levels compared with patients without SDB. It is surprising that additional sympathetic outflow is not translated into lowered muscle blood flow. In fact, our findings are consistent with previous work that showed no differences in muscle blood flow between HF patients with CSA and OSA and HF patients without SDB. 27 At this point, there is no explanation for such hemodynamic response. Further studies are needed to clarify this issue.
. Hemodynamic and Respiratory Changes From Baseline Values Provoked by Hypoxia and Hypercapnia in Chronic Heart Failure Patients Without Sleep-Disordered Breathing and in Chronic Heart Failure Patients With Sleep-Disordered Breathing
Response to Peripheral Chemoreceptors Stimulation
Increase in sympathetic nerve activity and muscle blood flow during exposure to hypoxia is a well-known response to peripheral chemoreflex stimulation in humans. 17, 36, 37 Other observational studies have shown that this reflex response is altered by SDB. Patients with SDB have attenuated muscle vasodilatation and increased MSNA response to hypoxia. 38, 39 This neurovascular response can be further altered in HF patients with systolic dysfunction. 17 Compared with healthy individuals, patients with HF have blunted muscle vasodilation response and exaggerated enhancement in MSNA response during peripheral chemoreceptors stimulation. 17, 18 This study extends the knowledge about the chemoreflex control in patients with HF and SDB. In fact, it clarifies that the adverse hemodynamic response is significantly greater in patients with HF who have SDB compared with those without SDB, which seems to be independent of diabetes mellitus and dyslipidemia. Furthermore, the greater MSNA responses during peripheral chemoreceptors stimulation are consistent with the notion that exaggerated sympathetic outflow contributes to the heightened vasoconstrictor response in HF patients with SDB. Both increased sympathetic activation and arterial vasoconstriction, if occurring repetitively throughout the night, likely contribute to the increased morbidity and mortality associated with SDB in advanced HF. The association between sympathetic outflow and SDB has been previously reported in patients with HF. 26, 27 
Response to Central Chemoreceptors Stimulation
Previous studies have consistently demonstrated that the activation of the central chemoreceptors by carbon dioxide inhalation leads to increase in MSNA and muscle blood flow in healthy subjects. 36, 39 Moreover, there is a body of evidence that these reflexes are preserved in patients with OSA. 36, 39 Conversely, in patients with HF, central chemoreceptors stimulation causes exaggerated increase in MSNA accompanied by a reduction in muscle blood flow. 16, 17, 25 It is unknown however, whether this neurovascular alteration is similar in all patients with HF regardless of presence of SDB, or whether it was greater in those with SDB compared with those without SDB. In addition, this increased sympathetic outflow would be expected to cause a more intense muscle vasoconstriction in response to hypercapnia. We found that SDB diminishes FBF and CBF and seems to enhance central chemoreflex control of MSNA during hypercapnia in patients with HF. More importantly, this vascular alteration occurs in both arm and leg vascular beds, consistent with widespread hemodynamic effect and regardless of diabetes mellitus and dyslipidemia.
In a previous study, we reported that the central chemoreflex control of V ⋅ E was preserved in patients with HF. 17 We found that the increase in V ⋅ E in response to hypercapnia was not different between patients with HF and healthy individuals. This study confirms these findings in HF patients with SDB. 
Possible Mechanisms
The mechanisms involved in the blunted vasodilatation during chemoreceptors stimulation in patients with chronic HF are beyond the scope of our study, but we offer the following observations: First, muscle vascular responses during chemoreceptors stimulation are mediated by nitric oxide production at the endothelial level. 18, 40, 41 Second, previous observational studies show that repeated episodes of hypoxia and reoxygenation decrease endothelial nitric oxide production 42, 43 and increase oxidative stress. 20, 44, 45 Third, altered endothelium-mediated responses during hypoxia in patients with HF has been reported. 18 In this last study, intra-arterial infusion of L-NMMA (N G -monomethyl L-arginine), an inhibitor of nitric oxide synthase, completely abolished the muscle vasodilator responses in healthy individuals. In contrast, L-NMMA infusion did not change the muscle vasodilation responses during hypoxia in patients with HF. 18 Together, these findings are consistent with an impaired endothelial response during chemoreceptors stimulation in HF patients with SDB. Finally, it is likely that the increased sympathetic nerve activity directed to skeletal muscle during peripheral and central chemoreceptors stimulation restrains the muscle vasodilatation in HF patients with SDB.
Limitations
The inclusion criteria of ≤65 years old and body mass index ≤30 kg/m 2 may have limited the number of older, heavier, and ischemic patients in our study. Thus, the extrapolation of our findings to other cohorts of patients with chronic HF should be viewed with caution. On the other hand, there is evidence that the neurovascular alterations in patients with chronic HF do not depend on age but the level of cardiac dysfunction. 46 In this study, it was necessary to combine HF patients with SDB from OSA and from CSA to maintain adequate power. Nonetheless, the sample size remains modest, so testing multiple hypotheses may inflate the possibility of a type I error. In further analysis in which the patients were separated according to the type of SDB, we found that patients with CSA tended to have a more intense forearm vasoconstriction in response to hypoxia than patients with OSA. Larger studies of each subtype of SDB are necessary.
Conclusions
Patients with coexistence of HF and SDB have more severe muscle vasoconstriction during peripheral and central chemoreceptors stimulation than HF patients without SDB, which seems to be associated with endothelial dysfunction and, in part, increased MSNA response.
Perspectives
The exaggerated muscle vasoconstriction and sympathetic activation during peripheral and central chemoreceptors stimulation in HF patients with SDB suggest that SDB is not merely a bystander or marker but that SDB directly contributes to increased morbidity and mortality. Although a recent large cohort study in patients with HF has shown that the treatment of CSA with adaptive servo-ventilation is associated with increased cardiovascular mortality, 19 there is strong evidence that sympathetic nerve activity and vasoconstriction are predictors of mortality in patients with HF. 47 Moreover, other studies show that amelioration in SDB contributes to better clinical outcome in patients with chronic HF. For example, exercise training improves sleep pattern in HF patients with SDB 27 and, in addition, improves endothelial function 48 and remarkably reduces MSNA in chronic HF patients with CSA and OSA. 27, 49, 50 Similar findings have been reported with continuous positive airway pressure. 21 It remains unknown, but of interest, whether continuous positive airway pressure treatment of these HF patients with SDB will ameliorate their heightened peripheral and central chemoreceptor sensitivity and its adverse neurovascular effects. 
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